Transition Services Agreement [Member]
Transition Services Agreement
Represents the entity's Transition Services Agreement.
Percentage of Economic Interest in Future Payments
Percentage of economic interest in any future payments made by GSK to be received
Represents percentage of economic interest in any future payments to be received by the entity.
Amount capitalized in cash in connection with Spin-Off
Represents amount capitalized which is received from the spin-off of company's business.
Proceeds from Spin Off of Businesses Capitalized
Expected Period Within which Majority of Services Provided Under Agreement
Expected period within which most of the services will be provided under agreement following the spin-off
Represents the expected period within which majority of the services will be provided under the agreement.
Pendopharm Pharmaceuticals LLC [Member]
Pendopharm
Represents the entity, Pendopharm Pharmaceuticals LLC.
Theravance Inc [Member]
Theravance
Represents information pertaining to Theravance, Inc.
VIBATIV [Member]
VIBATIV
Represents the VIBATIV product.
Velusetrag [Member]
Velusetrag
Represents the product, velusetrag (or TD-5108).
Collaborative Arrangement Period Over Which Revenue Will be Recognized on Straight Line Basis
Period over which revenue will be recognized on straight line basis
Represents the period over which revenue will be recognized on straight line basis related to the collaborative arrangement.
Allowance for Doubtful Accounts Receivable [Abstract]
Allowance for Doubtful Accounts
Amendment Description
Share Based Compensation Arrangement by Share Based Payment Award Grant Approval Period as Approved by Board of Directors
Period for which compensation committee has approved grants
Represents the period for which the board of directors approved grants under the share-based payment awards.
Amendment Flag
Represents the potential future contingent payments that the entity is eligible to receive.
Collaborative Arrangement Contingent Payment that Entity could Earn
Potential future contingent payments receivable
Total reduction to R&D expense
Represents the amount of research reimbursement recognized under the collaborative arrangement by the entity as a result of reduction in research and development expense.
Collaborative Arrangement Research and Development Expenses Reimbursed to Entity
Collaborative Agreement Initial Research Term
Initial research term
Represents the initial research term.
Collaborative Arrangement Annual Royalties as Percentage of Net Sales
Royalty rate, as a percentage of net sales
Represents the royalties to be received by the entity from the other party, expressed as a percentage of net sales.
Number of countries across MENA in which commercialization rights were granted
Number of units of accounting based on the relative selling price method
Represents the number of units of accounting to which upfront payment received by the entity was allocated based on the relative selling price method.
Collaborative Agreement Number of Units of Accounting to which Upfront Payment Received was Allocated
Alfa Wassermann [Member]
Alfa Wassermann societa per azioni
Represents the entity, Alfa Wassermann S.p.A.
Collaborative Arrangements
Receivables from collaborative arrangements
Receivables from Collaborative Arrangements
Represents the amount receivable under collaborative arrangements.
Number of development and commercialization agreements.
Number of development and commercialization agreements
Number of Development and Commercialization Agreements
Upfront payment received allocated to license
Represents the amount of upfront fees received during the period allocated to license under the collaborative arrangement.
Collaborative Arrangement, Upfront Fees Received Allocated to License
Area of buildings in South San Francisco, California (in square feet)
Area of Real Estate Property
Represents the amount of upfront fees received during the period allocated to research services under the collaborative arrangement.
Collaborative Arrangement, Upfront Fees Received Allocated to Research Services
Upfront payment received allocated to research services
Upfront payment received allocated to committee participation
Represents the amount of upfront fees received during the period allocated to committee services under the collaborative arrangement.
Collaborative Arrangement, Upfront Fees Received Allocated to Committee Services
Collaborative Arrangements, Revenue
Revenue from collaborative arrangements
Revenue earned under collaborative arrangements from upfront payments and contingent payments.
Net revenue from collaborative arrangements (including amounts from a related party of $270 and $1,322 for the three months ended March 31, 2014 and 2013)
Revenues
Total net revenue
Total revenue from collaborative arrangements
Development and Commercialization Agreement
Development and Commercialization Agreement [Member]
Represents the entity's agreement related to development and commercialization of a product or service.
Represents the entity's agreement related to discover, develop and commercialize a product or service.
Research Collaboration and License Agreement
Research Collaboration and License Agreement [Member]
Represents the entity's commercialization agreement.
Commercialization Agreement
Commercialization Agreement [Member]
Current Fiscal Year End Date
Award Type [Axis]
Document and Entity Information
Special Long Term Retention Awards 2011 [Member]
Special Long-Term Retention and Incentive Cash Awards Program
Represents the Special Long-Term Retention and Incentive Equity Awards Program under which equity-based awards are granted.
2011 Restricted Stock Awards
2012 Equity Incentive Plan
Represents the 2012 Equity Incentive Plan as approved by shareowners.
Equity Incentive Plan 2012 [Member]
2012 Plan
Clinigen [Member]
Clinigen
Represents Clinigen, a third party with which the entity has entered Commercialization agreement.
Incentive Compensation Program [Axis]
Represents the pertinent data describing and reflecting disclosures pertaining to incentive compensation programs under which equity-based awards are granted.
Represents the incentive compensation programs under which equity-based awards are granted.
Incentive Compensation Program [Domain]
Represents the entity, Merck.
Merck [Member]
Merck
Equity award vesting based on performance results.
Performance-contingent
Performance Contingent [Member]
Performance
Deferred Cash Bonus [Member]
A contractual arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a cash bonus, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to individual, group and entity-wide performance goals, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and profit sharing.
Cash bonus expense
R-Pharm CJSC
Represents the entity, R-Pharm CJSC.
R Pharm C J S C [Member]
R-Pharm
Collaborative Arrangement Revenue Recognition [Table Text Block]
Schedule of revenue recognized from collaborative arrangements
Tabular disclosure of revenue recognition by the entity related to the collaboration agreement.
Document Period End Date
Description of operations and summary of significant accounting policies
Summary of Significant Accounting Policies [Line Items]
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies [Table]
Information related to various accounting policies of the entity.
TD 1792 [Member]
Represents the product, TD-1792.
TD-1792
Represents the VIBATIV product, which is being developed and commercialized by entering into a collaboration arrangement with Astellas.
VIBATIV
VIBATIV Product [Member]
Collaborative Agreement Termination Term
Agreement term
Represents the period to terms of termination agreement of a collaboration agreement.
Period for which services will be provided under agreement following the spin-off
Long Term Retention Program Period
Period of the entity's long-term retention program, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Timeframe for achievement of performance conditions
Maximum compensation expense to be recognized if sufficient performance conditions are achieved
Long Term Retention Program Potential, Maximum Total Compensation Cost
Represents the aggregate potential maximum cost of compensation made to employees under long-term retention program.
Collaborative Agreement Termination Advance Notice Term
Period of advance notice to terminate the agreement
Represents the period of advance notice required to terminate the collaboration agreement.
Development and Collaboration Agreement [Member]
Development and Collaboration Arrangement
Represents the entity's agreement related to development and collaboration of a product or service.
Entity [Domain]
Upfront payment received
Upfront payment
Collaborative Arrangement Upfront Payments Received
Represents the cumulative amount of upfront payments received under the collaborative arrangement.
Cash Sales Discounts Percentage
Cash discounts (as a percent)
Represents the cash discount given by the entity to its customer as a percentage of the sales price, as an incentive for prompt payment.
Product Return Acceptance Period Prior to Product Expiration Date
Expired product return acceptance period prior to product expiration date
Represents the expired product return acceptance period prior to product expiration date.
Arrangements and Non-arrangement Transactions [Domain]
Expired product return acceptance period after product expiration date
Represents the expired product return acceptance period after product expiration date.
Product Return Acceptance Period after Product Expiration Date
Award by Period [Axis]
Information of awards by period granted.
Award by Period [Domain]
Equity-based compensation award by period.
Compensation expense related to cash bonus recognized in current year given sufficient performance conditions achieved
Represents the aggregate cost of compensation made to employees under long-term retention program during the current fiscal year.
Long Term Retention Program Cash Bonus Expense Recognized
Common stock dividend ratio
Represents the number of common stock distributed as form of dividend for each common stock held by parent company associated with the separation from parent company on completion of spin-off.
Common Stock Stock Dividend Ratio
Represents the entity, Hikma Pharmaceuticals LLC.
Hikma Pharmaceuticals LLC [Member]
Hikma
Mega Pharm Limited [Member]
MegaPharm
Represents the entity, MegaPharm Ltd.
Restricted Stock Granted 2010 [Member]
2010 Restricted Stock Awards
Represents the restricted stock awards granted in 2010 as approved by board of directors.
Telavancin Product [Member]
Represents information pertaining to Telavancin.
Telavancin
Long Term Retention Program Cash Bonus Expense Paid
Total cash bonus paid for the first tranche
Represents the amount of compensation paid to employees under long-term retention program.
Long Term Retention Program Potential Maximum Total Compensation Cost in Next Fiscal Year
Compensation expenses related to cash bonus to be recognized in next fiscal year if sufficient performance conditions are achieved
Aggregate potential maximum cost of compensation made to employees under long term retention program that may be recognized in the next fiscal year.
Long Term Retention Program Cash Bonus Expense to be Recognized over Vesting Period
Vesting period for the second tranche of awards
Vesting period of cash bonus expenses to be recognized under long-term retention program.
Separation and Distribution Agreement [Member]
Separation and Distribution Agreement
Represents the entity's Separation and Distribution Agreement.
Stock-based compensation expenses that will be recognized subject to sufficient performance conditions
Total Share Based Compensation Cost Next Twelve Months
Represents the total expense that will be recognized during the next twelve months arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees if sufficient performance conditions are met.
LongTerm Retention Program Cash Bonus Maximum Potential Expense Paid after Modification
Maximum remaining potential cash bonus expense associated with the grant after the modification
Represents the maximum potential amount of compensation paid to employees after the modification under long-term retention program.
Net realized gains (losses) on marketable securities
Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments [Abstract]
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Filer Category
Entity Public Float
Entity Registrant Name
Entity Central Index Key
Entity Common Stock, Shares Outstanding
Document Fiscal Year Focus
Document Fiscal Period Focus
Legal Entity [Axis]
Document Type
Summary of Significant Accounting Policies
Accounts receivable, net of allowances of $209 (unaudited) and $89
Accounts Receivable, Net, Current
Accounts Payable, Current
Accounts payable
Accounts Receivable [Member]
Accounts receivable
Less accumulated depreciation and amortization
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Accumulated other comprehensive income
Accumulated Other Comprehensive Income (Loss), Net of Tax
Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income (Loss) [Member]
Weighted Average Remaining Amortization Period
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life
Additional paid-in capital
Additional Paid in Capital, Common Stock
Additional Paid-In Capital
Additional Paid-in Capital [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Advertising expenses
Advertising Expense
Advertising Expenses
Advertising Costs, Policy [Policy Text Block]
Stock-based compensation expense
Stock-based compensation expense
Allocated Share-based Compensation Expense
Allowance for Doubtful Accounts Receivable, Current
Account receivable, allowance
Allowances for accounts receivable
Accounts Receivable Allowances
Allowance for Trade Receivables [Member]
Allowance for doubtful accounts
Allowance for Doubtful Accounts Receivable
Allowance for doubtful accounts
Allowance for Doubtful Accounts, Current [Member]
Amortization expense
Amortization of Financing Costs
Amortization expense
Amortization of Intangible Assets
Amortization of intangible asset
Amortization of intangible assets
Antidilutive Securities [Axis]
Securities that could potentially dilute basic EPS in the future
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities, Name [Domain]
Anti-dilutive securities (in shares)
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Total assets
Assets
Current assets:
Assets, Current [Abstract]
Assets
Assets [Abstract]
Total current assets
Assets, Current
Fair Value, In loss position for less than 12 months
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Schedule of amortized cost and estimated fair values for available-for-sale securities
Available-for-sale Securities [Table Text Block]
Fair Value
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract]
Maturity period for marketable securities
Available-for-sale Securities, Debt Maturities [Abstract]
Fair Value, In loss position for more than 12 months
Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value
Estimated Fair Value
Total assets measured at fair value
Available-for-sale Securities.
Fair Value, Total
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
Marketable securities
Available-for-sale Securities, Debt Securities, Noncurrent
Short-term investments
Available-for-sale Securities, Debt Securities, Current
Gross Unrealized Losses
Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss [Abstract]
Amortized Cost
Available-for-sale Securities, Amortized Cost Basis
Available-for-Sale Securities
Realized losses
Available-for-sale Securities, Gross Realized Losses
Realized gains
Available-for-sale Securities, Gross Realized Gains
Net realized gains (losses)
Available-for-sale Securities, Gross Realized Gain (Loss)
Balance Sheet Location [Axis]
Balance Sheet Location [Domain]
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Counterparty Name [Axis]
Stock prices below $27.79 per share
Call Option [Member]
Net increase (decrease) in cash and cash equivalents
Cash and Cash Equivalents, Period Increase (Decrease)
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Cash and Cash Equivalents
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash, Cash Equivalents and Restricted Cash
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents
Cash and Cash Equivalents [Member]
Class of Stock [Domain]
Information related to collaborative arrangements
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Information related to collaboration arrangements
Collaborative Arrangements and Multiple-Element Arrangements
Collaborative Arrangement, Accounting Policy [Policy Text Block]
Collaborative Arrangements
Collaborative Arrangement Disclosure [Text Block]
U.S. commercial paper
Commercial Paper [Member]
Commitments and Contingencies
Commitments and contingencies (Notes 4 and 6)
Commitments and Contingencies.
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share
Class A common stock
Class A Common Stock
Common Class A [Member]
Common Stock
Common Stock [Member]
Common stock, $0.01 par value; authorized: 200,000 shares; outstanding: 112,519 and 111,516 at March 31, 2014 and December 31, 2013
Common Stock, Value, Issued
Common stock, authorized shares
Common Stock, Shares Authorized
Dividend in ordinary shares distributed to Theravance's stockholders
Common Stock Dividends, Shares
Common stock, outstanding shares
Balance (in shares)
Balance (in shares)
Common Stock, Shares, Outstanding
Bonus Accruals
Compensation Related Costs, Policy [Policy Text Block]
Deferred tax assets:
Components of Deferred Tax Assets [Abstract]
Comprehensive Loss
Comprehensive Income, Policy [Policy Text Block]
Comprehensive loss
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Computer equipment
Computer Equipment [Member]
Concentration Risk Type [Domain]
Concentration of Credit and Other Risks
Concentration Risk [Line Items]
Concentration Risk Benchmark [Domain]
Concentration Risk Type [Axis]
Concentration Risk [Table]
Concentration Risk Benchmark [Axis]
Percentage of Total Accounts Receivable Balance
Concentration Risk, Percentage
Principles of Consolidation
Consolidation, Policy [Policy Text Block]
Number of shares of common stock converted
Conversion of Stock, Shares Converted
Total convertible subordinated notes
Convertible Debt, Fair Value Disclosures
Convertible Subordinated Notes Due 2015
Convertible Debt [Member]
Convertible subordinated notes
Convertible Subordinated Debt, Noncurrent
Convertible subordinated notes
Convertible Subordinated Debt [Member]
U.S. corporate notes
Corporate Note Securities [Member]
Cost of VIBATIV delivered to Astellas
Cost of Goods Sold
Cost of goods sold
Distributor
Credit Concentration Risk [Member]
Debt disclosures
Debt Instrument [Line Items]
Schedule of Long-term Debt Instruments [Table]
Principal amount of debt converted
Debt Conversion, Original Debt, Amount
Number of common shares issued upon debt conversion
Debt Conversion, Converted Instrument, Shares Issued
Debt Instrument, Face Amount
Loan amount
Notes issued
Long-Term Debt
Forgiveness of notes receivable
Debt Instrument, Decrease, Forgiveness
Debt Instrument, Convertible, Conversion Ratio
Initial conversion rate of shares
Conversion rate of shares
Initial conversion price of convertible notes into common stock (in dollars per share)
Conversion price of convertible notes into common stock (in dollars per share)
Debt Instrument, Convertible, Conversion Price
Unamortized issuance costs
Debt Instrument, Unamortized Discount
Accrued interest on convertible subordinated notes
Debt Instrument, Increase, Accrued Interest
Interest rate (as a percent)
Debt Instrument, Interest Rate, Stated Percentage
Commitments and Contingencies
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Information related to long-term retention and incentive cash bonus awards to certain employees
Deferred Compensation Arrangements [Abstract]
Deferred Bonus and Profit Sharing Plan, Type of Deferred Compensation [Axis]
Deferred Rent
Deferred Charges, Policy [Policy Text Block]
Deferred rent
Deferred Costs [Abstract]
Deferred rent
Deferred Rent Credit, Noncurrent
Deferred revenue
Deferred Revenue
Deferred revenue
Deferred Revenue, Current
Deferred revenue
Deferred revenues
Deferred Tax Assets, Deferred Income
Deferred revenue
Deferred Revenue, Noncurrent
Deferred tax assets
Deferred Tax Assets, Gross
Total deferred tax assets
Other
Deferred Tax Assets, Other
Deferred Tax Assets, Net of Valuation Allowance
Net deferred tax assets
Net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards
Valuation allowance
Deferred Tax Assets, Valuation Allowance
Depreciation expense
Depreciation
Depreciation and amortization
Depreciation, Depletion and Amortization
Payments on capped call option transactions
Derivative, Cost of Hedge
Cap price for the underlying number of shares (in dollars per share)
Derivative, Cap Price
Non-employee director
Director [Member]
Share-Based Compensation
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Share-Based Compensation
Notes receivable
Due from Employees, Current
Receivable from related party
Due from Related Parties, Current
Notes receivable
Due from Employees, Noncurrent
Payable to a related party
Due to Related Parties, Current
Basic and diluted net loss per share (in dollars per share)
Earnings Per Share, Basic and Diluted
Basic and diluted net loss per share (in dollars per share)
Basic and diluted net loss per common share (in dollars per share)
Net Loss per Share
Earnings Per Share [Text Block]
Basic net income (loss) per common share (in dollars per share)
Earnings Per Share, Basic
Diluted net income (loss) per common share (in dollars per share)
Earnings Per Share, Diluted
Net Loss per Share
Net Loss per Share
Effective tax rate (as a percent)
Effective Income Tax Rate Reconciliation, Percent
The differences between the U.S. federal statutory income tax rate to the Company's effective tax rate
Effective Income Tax Rate Reconciliation, Percent [Abstract]
State income taxes, net of federal benefit (as a percent)
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
Other (as a percent)
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Change in valuation allowance (as a percent)
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effect of prior period adjustments (as a percent)
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent
U.S. federal statutory income tax rate (as a percent)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
Federal and state research credits (as a percent)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Effect of tax rate changes (as a percent)
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent
Stock-based compensation (as a percent)
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent
Accrued personnel-related expenses
Employee-related Liabilities, Current
Stock options
Employee stock options
Employee Stock Option [Member]
Employee Stock Purchase Plan
Employee Stock [Member]
Total stock-based compensation expense capitalized to inventory
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount
Total unrecognized compensation cost related to unvested stock-based compensation
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized
Maximum potential expense, net of forfeitures
Weighted-average remaining service period of recognition of unrecognized compensation cost
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition
Equity Component [Domain]
Total
Estimate of Fair Value Measurement [Member]
Measurement Frequency [Axis]
Fair Value Measurements, Recurring and Nonrecurring [Table]
Fair Value, Hierarchy [Axis]
Recurring basis
Fair Value, Measurements, Recurring [Member]
Fair value measurements transfer to Level 1 From Level 2
Fair Value, Assets, Level 2 to Level 1 Transfers, Amount
Fair Value, Measurement Frequency [Domain]
Fair value measurements, liabilities transfer from Level 1 to Level 2
Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount
Fair value measured transfer to Level 2 From Level 1
Fair Value, Assets, Level 1 to Level 2 Transfers, Amount
Estimated fair values of entity's financial assets and liabilities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]
Schedule of estimated fair values
Fair value measurements, liabilities transfer from Level 2 to Level 1
Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount
Fair Value Measurements
Nonrecurring basis
Fair Value, Measurements, Nonrecurring [Member]
Fair Value Hierarchy [Domain]
Fair Value of Financial Instruments
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value Measurements
Fair Value Disclosures [Text Block]
Significant Unobservable Inputs, Level 3
Fair Value, Inputs, Level 3 [Member]
Quoted Prices in Active Markets for Identical Assets, Level 1
Fair Value, Inputs, Level 1 [Member]
Significant Other Observable Inputs, Level 2
Fair Value, Inputs, Level 2 [Member]
Estimated useful life
Finite-Lived Intangible Asset, Useful Life
Gross Carrying Value
Finite-Lived Intangible Assets, Gross
Estimated amortization expense for the year 2018
Finite-Lived Intangible Assets, Amortization Expense, Year Five
Intangible assets
Finite-Lived Intangible Assets [Line Items]
Estimated amortization expense for the year 2016
Finite-Lived Intangible Assets, Amortization Expense, Year Three
Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Intangible assets, net
Net Carrying Value
Estimated amortization expense after the year 2018
Finite-Lived Intangible Assets, Amortization Expense, after Year Five
Estimated amortization expense for the year 2014
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months
Estimated amortization expense for the year 2017
Finite-Lived Intangible Assets, Amortization Expense, Year Four
Estimated amortization expense for the year 2015
Finite-Lived Intangible Assets, Amortization Expense, Year Two
Foreign Currency
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Furniture and fixtures
Furniture and Fixtures [Member]
Loss on disposal of assets
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Loss on disposal of equipment
Gain (Loss) on Disposition of Property Plant Equipment
General and administrative
General and Administrative Expense [Member]
Intangible Assets
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Intangible Assets
Intangible Assets
Impairment of Long-Lived Assets
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Amount of write-off recognized related to assets that could no longer be used in operations
Impairment of Long-Lived Assets Held-for-use
Lease incentives
Incentive to Lessee
CONDENSED COMBINED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
Income Statement Location [Axis]
Income Taxes
Income Tax Authority [Domain]
Income Tax Authority [Axis]
Income Taxes
Income Tax Disclosure [Text Block]
Income Statement Location [Domain]
Provision for income taxes
Income Tax Expense (Benefit)
Accrued interest or penalties due to our net operating losses
Income Tax Examination, Penalties and Interest Accrued
Income Taxes
Income Tax, Policy [Policy Text Block]
Accounts receivable
Increase (Decrease) in Accounts Receivable
Accounts payable
Increase (Decrease) in Accounts Payable
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities
Increase (Decrease) in Accrued Liabilities
Deferred rent expense
Increase (Decrease) in Deferred Charges
Deferred revenue
Increase (Decrease) in Deferred Revenue
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Inventories
Increase (Decrease) in Inventories
Receivables from collaborative arrangements
Increase (Decrease) in Other Receivables
Other assets
Increase (Decrease) in Other Operating Assets
Prepaid and other current assets
Increase (Decrease) in Prepaid Expense and Other Assets
Release of restricted cash
Increase (Decrease) in Restricted Cash
Increase (Decrease) in Stockholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Dilutive effect of equity incentive plans and ESPP (in shares)
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
Intangible Assets
Intangible Assets Disclosure [Text Block]
Accrued interest on convertible subordinated notes
Interest Payable, Current
Interest expense
Interest Expense
Cash paid for interest
Interest Paid
Interest receivable related to the loans
Interest Receivable
Capitalized Software
Internal Use Software, Policy [Policy Text Block]
Federal
Internal Revenue Service (IRS) [Member]
Total inventories
Inventories
Inventory, Net
Inventories
Inventory, Net [Abstract]
Finished goods
Inventory, Finished Goods, Net of Reserves
Raw materials
Inventory, Raw Materials, Net of Reserves
Inventories
Inventory Disclosure [Text Block]
Cost of unrealizable VIBATIV inventories
Inventory Write-down
Inventory [Line Items]
Inventories
Inventories
Inventory, Policy [Policy Text Block]
Inventory, Current [Table]
Inventories
Work-in-process
Inventory, Work in Process, Net of Reserves
Interest income
Investment Income, Net
Available-for-Sale Securities
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]
Long-term Debt, Type [Axis]
Long-term Debt, Type [Domain]
Leasehold improvements
Leasehold Improvements [Member]
Total current liabilities
Liabilities, Current
Total liabilities and parent company deficit
Liabilities and Equity
Current liabilities:
Liabilities, Current [Abstract]
Total liabilities
Liabilities
Liabilities and parent company deficit
Liabilities and Equity [Abstract]
Notes Receivable
Loans Receivable, Net [Abstract]
Long-Term Debt
Long-term Debt [Text Block]
Loss Contingencies [Table]
Operating Leases
Loss Contingencies [Line Items]
Major Types of Debt and Equity Securities [Axis]
Major Types of Debt and Equity Securities [Domain]
Customer [Axis]
Senior management
Management [Member]
(Gain) loss on sales of available-for-sale securities
Marketable Securities, Realized Gain (Loss)
Investments in Marketable Securities
Marketable Securities, Policy [Policy Text Block]
Advertising Expenses
Marketing and Advertising Expense [Abstract]
Maximum
Maximum [Member]
Minimum
Minimum [Member]
Money market funds
Money Market Funds [Member]
Movement in valuation and qualifying accounts
Movement in Valuation Allowances and Reserves [Roll Forward]
Customer [Domain]
Financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]
Operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net increase (decrease) in cash and cash equivalents
Net Cash Provided by (Used in) Continuing Operations
Net loss
Net loss
Net income (loss)
Net Income (Loss) Available to Common Stockholders, Basic
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities, Continuing Operations
Net cash used in investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Investing activities
Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]
Net Income (Loss) Attributable to Parent
Net loss
Net loss
Supplemental Non-cash Financing Activities
Noncash Investing and Financing Items [Abstract]
Notes receivable, current
Notes, Loans and Financing Receivable, Net, Current
Number of buildings
Number of Real Estate Properties
Number of operating segments
Number of Operating Segments
Thereafter
Operating Leases, Future Minimum Payments, Due Thereafter
Future minimum lease payments
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Costs and expenses:
Operating Expenses [Abstract]
2017
Operating Leases, Future Minimum Payments, Due in Four Years
Operating Expenses
Total costs and expenses
Operating expenses
2018
Operating Leases, Future Minimum Payments, Due in Five Years
Sublease income
Operating Leases, Rent Expense, Sublease Rentals
Operating Costs and Expenses [Abstract]
Operating costs and expenses:
2016
Operating Leases, Future Minimum Payments, Due in Three Years
Rent expense
Operating Leases, Rent Expense, Net
2014
Operating Leases, Future Minimum Payments Due, Next Twelve Months
Loss from operations
Income (loss) from operations
Operating Income (Loss)
Operating Costs and Expenses
Total operating costs and expenses
2015
Operating Leases, Future Minimum Payments, Due in Two Years
Total
Operating Leases, Future Minimum Payments Due
Net operating loss carryfowards
Operating Loss Carryforwards
Amount of net operating losses, which expire in varying amounts between 2018 and 2032, that can be utilized
Option Indexed to Issuer's Equity, Type [Axis]
Strike price for the underlying number of shares (in dollars per share)
Option Indexed to Issuer's Equity, Strike Price
Option Indexed to Issuer's Equity, Type [Domain]
Description of Operations and Summary of Significant Accounting Policies
Description of Operations and Summary of Significant Accounting Policies
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
Description of Operations
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Other Commitments [Axis]
Other Commitments [Domain]
Other assets
Other Assets, Noncurrent
Other non-cash items
Other Noncash Income (Expense)
Net unrealized gain (loss) on marketable securities
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax
Non-operating income
Other Nonoperating Income
Interest and other income
Other income (expense), net
Other Nonoperating Income (Expense)
Other Nonoperating Income (Expense) [Abstract]
Other Income (Expense), net
Other Liabilities, Current
Other accrued liabilities
Inventory sold at cost
Proceeds from VIBATIV delivered to Astellas
Revenue (including amounts from a related party of $9,658 in 2011, $9,826 in 2010, and $15,073 in 2009)
Other Revenue, Net
Accrued clinical and development expenses
Other Accrued Liabilities, Current
Other comprehensive income (loss):
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Net unrealized gain (loss) on available-for-sale securities, net of tax
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent
Products and Services [Domain]
Theravance
Parent Company [Member]
Purchase of capped-call options
Payments for Derivative Instrument, Financing Activities
Purchases of available-for-sale securities
Payments to Acquire Available-for-sale Securities
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Issuances of notes receivable
Payments to Acquire Notes Receivable
Increase in intangible assets
Payments to Acquire Intangible Assets
Plan Name [Domain]
Plan Name [Axis]
Preferred stock, par value (in dollars per share)
Preferred Stock, Par or Stated Value Per Share
Preferred stock, $0.01 par value, 230 shares authorized, no shares issued and outstanding
Preferred Stock, Value, Issued
Preferred stock, shares issued
Preferred Stock, Shares Issued
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Prepaid and other current assets
Prepaid Expense and Other Assets, Current
Reclassifications
Reclassification, Policy [Policy Text Block]
Proceeds from issuance of debt, net of issuance costs
Proceeds from Debt, Net of Issuance Costs
Payments received on notes receivable
Proceeds from Collection of Notes Receivable
Transfers from parent company
Proceeds from Contributions from Parent
Proceeds from issuances of convertible subordinated notes, net of debt issuance costs
Proceeds from Issuance of Subordinated Long-term Debt
Proceeds from issuances of common stock, net
Proceeds from Issuance of Common Stock
Total cash proceed
Proceeds from Stock Options Exercised
Maturities of available-for-sale securities
Proceeds from Sale and Maturity of Available-for-sale Securities
Sales of available-for-sale securities
Proceeds from Sale of Available-for-sale Securities
Amount of available-for-sale securities sold
Payments received on notes receivable
Proceeds from Sale and Collection of Notes Receivable
Products and Services [Axis]
Estimated useful life
Property, Plant and Equipment, Useful Life
Property and equipment, gross
Property, Plant and Equipment, Gross
Property and Equipment
Property, Plant and Equipment, Policy [Policy Text Block]
Property and equipment, net
Property and equipment, net
Property, Plant and Equipment, Net
Information related to Property, Plant and Equipment
Property and Equipment
Property, Plant and Equipment, Type [Domain]
Property, Plant and Equipment, Type [Axis]
Property and Equipment
Property, Plant and Equipment Disclosure [Text Block]
Property and Equipment
Information related to useful life of property and equipment
Property, Plant and Equipment [Line Items]
Stock prices above $38.00 per share
Put Option [Member]
SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)
Quarterly Financial Information [Text Block]
SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)
Range [Axis]
Range [Domain]
Notes Receivable
Receivables, Policy [Policy Text Block]
Amortization of deferred revenue
Recognition of Deferred Revenue
Gross unrecognized tax benefits
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Related party transactions
Related Party Transaction [Line Items]
Related Party [Axis]
Fees incurred related to related party
Related Party Transaction, Expenses from Transactions with Related Party
Related Party [Domain]
Related parties
Related Party Transactions [Abstract]
Payments on note payable and capital leases
Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities
Counterparty Name [Domain]
Purchase Obligations
Research and Development Arrangement [Member]
Research and development
Research and Development Expense
Research and development
Research and Development Expense [Member]
Research and Development Costs
Research and Development Expense, Policy [Policy Text Block]
Summary of reductions to R&D expenses related to the reimbursement payments
Research and Development Arrangement, Contract to Perform for Others [Table Text Block]
Research
Research Tax Credit Carryforward [Member]
RSUs
Restricted Stock Units (RSUs) [Member]
RSAs
RSAs (excludes performance-contingent RSAs)
Restricted Stock [Member]
Restricted cash
Restricted Cash and Cash Equivalents, Noncurrent
Accumulated Deficit
Retained Earnings [Member]
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Net revenue recognized under the collaboration
Revenue Recognition [Abstract]
Royalties
Revenue Recognition, Services, Royalty Fees [Policy Text Block]
Revenue Recognition
Revenue Recognition, Policy [Policy Text Block]
Product Revenues
Revenue Recognition Accounting Policy, Gross and Net Revenue Disclosure [Policy Text Block]
Revenue from a related party
Revenue from Related Parties
Total revenue
Revenues
Net revenue from collaborative arrangements
Revenue:
Revenues [Abstract]
Royalties from net sales of VIBATIV
Royalty Revenue
Royalty revenue
Total estimated fair value of options vested
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Weighted-average Exercise Price, Options Exercisable (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price
Aggregate intrinsic value of options exercisable
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Expected term
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term
Weighted-average Remaining Contractual Life
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term
Weighted-average Exercise Prices (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent
Purchase price as a percentage of fair market value of stock
Maximum term for stock options
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term
Weighted-average Remaining Contractual Life
Sales Revenue, Goods, Net
Product sales
Product Revenues
Revenue, Net [Abstract]
Balance at the beginning of the period
Balance at the end of the period
Astellas-labeled product sales allowance
Sales Allowances, Goods
Previously reported
Scenario, Previously Reported [Member]
Scenario, Forecast [Member]
Forecast
Scenario, Unspecified [Domain]
Schedule of Available-for-sale Securities [Table]
Schedule of anti-dilutive securities
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]
Schedule of net realized gains (losses) on marketable securities
Schedule of Realized Gain (Loss) [Table Text Block]
Schedule of expenses and income associated with operating leases
Schedule of Rent Expense [Table Text Block]
Schedule of weighted-average assumptions used to estimate the fair value of stock options granted
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Schedule of inventory
Schedule of Inventory, Current [Table Text Block]
Summary of inventories
Schedule of the differences between the U.S. federal statutory income tax rate to the Company's effective tax rate
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Significant components of the Company's deferred tax assets
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of Finite-Lived Intangible Assets [Table]
Summary of equity award activity under the 2012 plan and prior plans
Schedule of Share-based Compensation, Activity [Table Text Block]
Schedule of future minimum lease payments under non-cancelable operating lease
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Schedule of Product Information [Table]
Schedule of consolidated quarterly financial information
Schedule of Quarterly Financial Information [Table Text Block]
Computations for basic and diluted net loss per share
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Summary of available-for-sale securities with unrealized losses
Schedule of Unrealized Loss on Investments [Table Text Block]
Schedule of intangible assets
Schedule of Finite-Lived Intangible Assets [Table Text Block]
Available-for-sale securities
Schedule of Available-for-sale Securities [Line Items]
Schedule of stock-based compensation expense by award type included in the consolidated statements of operations
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]
Schedule of long-term debt
Schedule of Long-term Debt Instruments [Table Text Block]
Schedule of allocation of stock-based compensation expense included in the consolidated statements of operations
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Schedule of allocation of stock-based compensation expense included in the condensed combined statements of operations and comprehensive loss
Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]
Schedule of Related Party Transactions, by Related Party [Table]
Property, Plant and Equipment [Table]
Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]
VALUATION AND QUALIFYING ACCOUNTS
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
Schedule of outstanding options to purchase common stock based on range of stock option exercise prices
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]
Net Accounts Receivable Concentration Risk by Distributor
Segment Reporting
Segment Reporting [Abstract]
Segment Reporting
Segment Reporting, Policy [Policy Text Block]
Selling and marketing
Selling and Marketing Expense
Selling and marketing
Selling and Marketing Expense [Member]
Selling, General and Administrative Expenses [Member]
Selling, general and administrative
Selling, general and administrative
Selling, General and Administrative Expense
Additional disclosures
Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract]
Timeframe for achievement of performance conditions
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period
Number of shares outstanding subject to RSUs and vesting or performance conditions with vesting
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Weighted-average exercise price of outstanding options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Number of Compensation Awards Granted (in shares)
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
Granted (in dollars per share)
Weighted-Average Fair Value (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Granted (in dollars per share)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Forfeited (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Balance at the beginning of the period (in shares)
Balance at the end of the period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Volatility, maximum (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Volatility, minimum (as a percent)
Additional number of shares of common stock approved and authorized for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Released RSUs and RSAs (in shares)
Stock-based compensation
Share-based Compensation.
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Risk-free interest rate, maximum (as a percent)
Vesting period
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period
Vesting period for the second tranche of awards
Weighted-average fair value per share at grant
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Compensation Awards
Share-Based Compensation
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Balance at the beginning of the period (in dollars per share)
Balance at the end of the period (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Weighted-Average Fair Value (in dollars per share)
Weighted-average estimated fair value of issuances (in dollars per share)
Information related to share-based compensation
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Forfeited (in dollars per share)
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Risk-free interest rate, minimum (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Exercised (in dollars per share)
Weighted-average exercise price of awards exercised (in dollars per share)
Stock-based compensation (in shares)
Granted (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures
Dividend yield (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Forfeited (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Released RSUs and RSAs (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Shares remaining available for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant
Total intrinsic value of options exercised
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Volatility (as a percent)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Shares of common stock approved and authorized for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized
Shares of common stock approved and authorized for issuance
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Weighted-average assumptions
Weighted-average estimated fair value of awards granted (in dollars per share)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)
Balance at the end of the period (in dollars per share)
Fair Value of Stock-Based Compensation Awards
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]
Options outstanding and exercisable
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Balance at the beginning of the period (in shares)
Balance at the end of the period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Stock-based compensation
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Aggregate intrinsic value of options outstanding
Exercise Price Range [Axis]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]
Number of Shares Subject to Outstanding Options
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Equity Award [Domain]
Exercise price range, low end of range (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit
Number Outstanding (in shares)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options
Options Exercisable (in shares)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options
Exercise price range, high end of range (in dollars per share)
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit
Company's stock purchased by related party, price (in dollars per share)
Shares Issued, Price Per Share
Short-term investments
Short-term Investments [Member]
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Capitalized software
Software Development [Member]
Software
Software and Software Development Costs [Member]
State
State and Local Jurisdiction [Member]
Scenario [Axis]
Statement [Table]
Statement
Statement [Line Items]
Consolidated Statements of Stockholders' Equity (Net Capital Deficiency)
CONDENSED COMBINED STATEMENT OF CASH FLOWS
Equity Components [Axis]
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
CONDENSED COMBINED BALANCE SHEETS
Class of Stock [Axis]
Stock Issued During Period, Shares, Period Increase (Decrease)
Conversion of convertible subordinates notes due 2015
Stock Issued During Period, Value, Conversion of Convertible Securities
Stock-based compensation
Stock Granted, Value, Share-based Compensation, Net of Forfeitures
Conversion of convertible subordinated notes due 2015
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
Conversion of convertible subordinated notes into common stock
Stock Issued
Exercise of stock options, and issuance of common stock in settlement of restricted stock units, stock awards and purchase plan (in shares)
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures
Exercised (in shares)
Awards exercised (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
Stock issued during period (in shares)
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Conversion of convertible subordinated notes due 2015 (in shares)
Stock Issued During Period, Shares, Conversion of Convertible Securities
Exercise of stock options, and issuance of common stock in settlement of restricted stock units, stock awards and purchase plan
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures
Stockholders' equity:
Stockholders' Equity
Stockholders' Equity Attributable to Parent [Abstract]
Stockholders' Equity, Period Increase (Decrease)
Parent company deficit
Total stockholders' equity
Balance
Balance
Stockholders' Equity Attributable to Parent
Subsequent Events
Subsequent Events [Text Block]
Subsequent Events
Subsequent Event [Table]
Subsequent Events
Subsequent Event [Line Items]
Subsequent Event
Subsequent Event [Member]
Subsequent event
Subsequent Event Type [Domain]
Subsequent Event
Subsequent Event Type [Axis]
Reconciliation of gross unrecognized tax benefits
Summary of Income Tax Contingencies [Table Text Block]
Supplemental Disclosure of Cash Flow Information
Supplemental Cash Flow Information [Abstract]
Tax credit carryforward amount
Tax Credit Carryforward, Amount
Tax Credit Carryforward, Name [Domain]
Tax Credit Carryforward [Axis]
Accounts Receivable
Trade and Other Accounts Receivable, Policy [Policy Text Block]
Type of Arrangement and Non-arrangement Transactions [Axis]
Type of Deferred Compensation, All Types [Domain]
Transaction costs
Unamortized Debt Issuance Expense
Change in fair value of capped-call derivative assets
Change in capped-call option valuation
Unrealized Gain (Loss) on Derivatives
Gross increase in tax positions for current year
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Gross decrease for tax positions for prior years
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Gross unrecognized tax benefits at the beginning of the period
Gross unrecognized tax benefits at the end of the period
Unrecognized Tax Benefits
Total purchase obligations for services, development and supply agreements
Unrecorded Unconditional Purchase Obligation
Use of Management's Estimates
Use of Estimates, Policy [Policy Text Block]
U.S. government agency securities
U.S. government agencies
US Government Agencies Debt Securities [Member]
U.S. government securities
US Treasury and Government [Member]
Vesting [Axis]
Vesting [Domain]
Valuation and Qualifying Accounts Disclosure [Table]
Information related to valuation allowance
Valuation Allowance [Abstract]
Valuation Allowances and Reserves [Domain]
Charged to Costs and Expenses
Valuation Allowances and Reserves, Charged to Cost and Expense
Balance at Beginning of Year
Balance at End of Year
Valuation Allowances and Reserves, Balance
Deductions From Allowance Accounts
Valuation Allowances and Reserves, Deductions
Charged to Other Accounts
Valuation Allowances and Reserves, Charged to Other Accounts
Increase in valuation allowance
Valuation Allowance, Deferred Tax Asset, Change in Amount
VALUATION AND QUALIFYING ACCOUNTS
VALUATION AND QUALIFYING ACCOUNTS
Valuation and Qualifying Accounts Disclosure [Line Items]
Valuation Allowances and Reserves Type [Axis]
Less: unvested RSAs (in shares)
Weighted Average Number of Shares, Restricted Stock
Weighted-average shares of stock outstanding
Weighted Average Number of Shares Issued, Basic
Shares used to compute basic earnings per share (in shares)
Weighted-average common shares outstanding - basic
Weighted Average Number of Shares Outstanding, Basic
Shares used to compute basic and diluted net loss share (in shares)
Weighted Average Number of Shares Outstanding, Basic and Diluted
Weighted average shares used to compute basic and diluted net loss per share
Shares used to compute diluted earnings per share (in shares)
Weighted-average common shares outstanding and dilutive potential common shares - diluted
Weighted Average Number of Shares Outstanding, Diluted